Ensayos clinicos

1.641 ensayos encontrados

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Double-blind, Parallel Group, Placebo-controlled, Multicenter Phase 3 Trial to Evaluate Efficacy, Safety and Tolerability of Ianalumab on Top of Standard-of-care Therapy in Participants With Active Lupus Nephritis (SIRIUS-LN).

INTERVENTIONALInicio: 14 de jul de 2022ID: NCT05126277

ReclutandoFase 3ClinicalTrials.gov

Two Part (Double-blind Inclisiran Versus Placebo [Year 1] Followed by Open-label Inclisiran [Year 2]) Randomized Multicenter Study to Evaluate Safety, Tolerability and Efficacy of Inclisiran in Children (6 to Less Than 12 Years) With Heterozygous Familial Hypercholesterolemia and Elevated LDL- Cholesterol

INTERVENTIONALInicio: 9 de dic de 2024ID: NCT06597019

ReclutandoFase 3ClinicalTrials.gov

A PHASE 3, MULTI-CENTER, OPEN-LABEL EXTENSION STUDY TO INVESTIGATE THE LONG-TERM SAFETY, TOLERABILITY, AND EFFICACY OF DAZUKIBART IN PARTICIPANTS WITH IDIOPATHIC INFLAMMATORY MYOPATHIES (INCLUDING PARTICIPANTS WITH DERMATOMYOSITIS OR POLYMYOSITIS)

INTERVENTIONALInicio: 22 de ene de 2025ID: NCT06698796

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Double-blind, Placebo-Controlled, Multicenter Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Focal-Onset Seizures

INTERVENTIONALInicio: 9 de may de 2023ID: NCT05716100

ReclutandoFase 3ClinicalTrials.gov

A Phase 3 Randomized, Open-Label Multicenter Study of Zanubrutinib (BGB-3111) Plus Anti-CD20 Antibodies Versus Lenalidomide Plus Rituximab in Patients With Relapsed/Refractory Follicular or Marginal Zone Lymphoma

INTERVENTIONALInicio: 10 de mar de 2022ID: NCT05100862

ReclutandoFase 3ClinicalTrials.gov

A Phase 3, Prospective, Randomized, Open-label, Adaptive Group Sequential, Multicenter Trial With Blinded Endpoint Assessment to Evaluate the Efficacy and Safety of TAK-330 for the Reversal of Direct Oral Factor Xa Inhibitor-induced Anticoagulation in Patients Requiring Urgent Surgery/Invasive Procedure

INTERVENTIONALInicio: 24 de ago de 2022ID: NCT05156983

ReclutandoFase 3ClinicalTrials.gov

A PHASE 3, MULTICENTER, DOUBLE-BLIND, RANDOMIZED, PLACEBO-CONTROLLED STUDY TO EVALUATE THE EFFICACY AND SAFETY OF PF-06823859 IN PARTICIPANTS WITH ACTIVE IDIOPATHIC INFLAMMATORY MYOPATHIES (INCLUDING PARTICIPANTS WITH ACTIVE DERMATOMYOSITIS OR POLYMYOSITIS)

INTERVENTIONALInicio: 20 de may de 2023ID: NCT05895786

ReclutandoFase 3ClinicalTrials.gov

A PHASE 3, RANDOMIZED, DOUBLE BLIND, PLACEBO CONTROLLED STUDY OF PF-06821497 (MEVROMETOSTAT) WITH ENZALUTAMIDE IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MEVPRO-2)

INTERVENTIONALInicio: 22 de oct de 2024ID: NCT06629779

ReclutandoFase 3ClinicalTrials.gov

An International, Prospective, Open-label, Multi-center, Randomized Phase III Study Comparing Lutetium (177Lu) Vipivotide Tetraxetan (AAA617) Versus Observation to Delay Castration or Disease Recurrence in Adult Male Patients With Prostate-specific Membrane Antigen (PSMA) Positive Oligometastatic Prostate Cancer (OMPC)

INTERVENTIONALInicio: 12 de mar de 2024ID: NCT05939414

ReclutandoFase 3ClinicalTrials.gov

AN OPEN-LABEL STUDY IN PEDIATRIC (<18 YEARS OF AGE), SEVERE HEMOPHILIA A PARTICIPANTS (COAGULATION FACTOR ACTIVITY <1%) WITH OR WITHOUT INHIBITORS OR MODERATELY SEVERE TO SEVERE HEMOPHILIA B PARTICIPANTS (COAGULATION FACTOR ACTIVITY =2%) WITH OR WITHOUT INHIBITORS COMPARING 12 MONTHS OF HISTORICAL STANDARD TREATMENT TO MARSTACIMAB PROPHYLAXIS

INTERVENTIONALInicio: 9 de dic de 2022ID: NCT05611801

ReclutandoFase 3ClinicalTrials.gov

AN INTERVENTIONAL EFFICACY AND SAFETY, PHASE 3, DOUBLE-BLIND, 2-ARM STUDY TO INVESTIGATE ORALLY ADMINISTERED IBUZATRELVIR COMPARED WITH PLACEBO IN NON-HOSPITALIZED SYMPTOMATIC ADULT AND ADOLESCENT PARTICIPANTS WITH COVID-19 WHO ARE AT HIGH RISK OF PROGRESSING TO SEVERE ILLNESS

INTERVENTIONALInicio: 8 de dic de 2024ID: NCT06679140

ReclutandoFase 3ClinicalTrials.gov

A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study To Evaluate The Efficacy And Safety Of DNTH103 In Adults With Chronic Inflammatory Demyelinating Polyneuropathy (CAPTIVATE)

INTERVENTIONALInicio: 10 de feb de 2025ID: NCT06858579

ReclutandoFase 3ClinicalTrials.gov

A Phase III Study to Assess the Efficacy and Safety of NEXIUM for Maintenance of Healing of Erosive Esophagitis in Pediatric Patients 1 to 11 Years of Age

INTERVENTIONALInicio: 1 de jul de 2022ID: NCT05267613

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase 3 Study to Evaluate the Safety, Tolerability, and Efficacy of XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures

INTERVENTIONALInicio: 14 de feb de 2023ID: NCT05667142

ReclutandoFase 3ClinicalTrials.gov

AN OPEN-LABEL, 3-ARM, MULTICENTER, RANDOMIZED PHASE 3 STUDY TO EVALUATE THE EFFICACY AND SAFETY OF ELRANATAMAB (PF-06863135) MONOTHERAPY AND ELRANATAMAB + DARATUMUMAB VERSUS DARATUMUMAB + POMALIDOMIDE + DEXAMETHASONE IN PARTICIPANTS WITH RELAPSED/REFRACTORY MULTIPLE MYELOMA WHO HAVE RECEIVED AT LEAST 1 PRIOR LINE OF THERAPY INCLUDING LENALIDOMIDE AND A PROTEASOME INHIBITOR

INTERVENTIONALInicio: 4 de oct de 2021ID: NCT05020236

ReclutandoFase 3ClinicalTrials.gov

A PHASE 3, RANDOMIZED, OPEN-LABEL STUDY OF PF-06821497 (MEVROMETOSTAT) IN COMBINATION WITH ENZALUTAMIDE COMPARED WITH ENZALUTAMIDE OR DOCETAXEL IN PARTICIPANTS WITH METASTATIC CASTRATION RESISTANT PROSTATE CANCER PREVIOUSLY TREATED WITH ABIRATERONE ACETATE (MEVPRO-1)

INTERVENTIONALInicio: 21 de oct de 2024ID: NCT06551324

ReclutandoFase 3ClinicalTrials.gov

A Randomized, Double-blind, Double-dummy, Placebo-controlled, Multicenter, Phase 3 Study Assessing the Efficacy, Safety, and Tolerability of 2 Doses of Remibrutinib Over a 68-week Treatment Period in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa. (RECHARGE-1)

INTERVENTIONALInicio: 31 de ene de 2025ID: NCT06799000

ReclutandoFase 2ClinicalTrials.gov

A Phase 1b/2, Open-Label Umbrella Study To Evaluate Safety And Efficacy Of Elacestrant In Various Combination In Patients With Metastatic Breast Cancer

INTERVENTIONALInicio: 24 de ene de 2023ID: NCT05563220

ReclutandoRENIS

CARACTERIZACION DE ENFERMEDADES HEPÁTICAS AUTOINMUNES

OBSERVATIONALID: IS005258

ReclutandoRENIS

Eficacia y seguridad del IMVT-1402 en participantes adultos con enfermedad de Sjögren primaria con actividad sistémica moderada a grave.

INTERVENTIONALID: IS005244